Lv619
2024 积分 2022-08-12 加入
From biologics to small-molecule modulators: the evolving landscape of interleukin-targeted therapeutics
6天前
已关闭
A New Standard in Muscle-Invasive Bladder Cancer — The End of the Cisplatin Era?
6天前
已完结
Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer
6天前
已完结
Research Summary Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer
6天前
已完结
Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer
6天前
已完结
Toppling the HAT to Treat Lethal Prostate Cancer
7天前
已完结
Phase 3 Study of Niraparib-Plus-Pembrolizumab as Maintenance Therapy for Advanced/Metastatic Non–Small Cell Lung Cancer (ZEAL-1L)
7天前
已完结
Cooperation of the Transcriptional Coactivators CBP and p300 with Stat6
7天前
已完结
Recent advances in function-enhanced antibody-drug conjugates: Antibody optimization and payload combination
7天前
已完结
Upadacitinib for ulcerative colitis
8天前
已完结
皖公网安备34019202002308
